How does Testosterone Therapy Impact Quality of Life and Cancer Recurrence Rates in High-Risk Prostate Cancer Survivors? : A Systematic Review
Keywords:
Prostate Cancer Survivors, Testosterone Replacement Therapy (TRT), Biochemical Recurrence, Quality of Life, High-Risk Prostate Cancer, Systematic ReviewAbstract
Introduction: The use of testosterone therapy (TRT) to manage hypogonadal symptoms in prostate cancer survivors is clinically contentious due to long-standing fears that it may promote cancer recurrence. Definitive treatments often lead to debilitating side effects like fatigue and loss of libido, creating a dilemma between improving quality of life (QoL) and ensuring oncological safety. This systematic review evaluates the impact of testosterone therapy on biochemical recurrence rates and QoL in high-risk prostate cancer survivors. Methods: Following PRISMA 2020 guidelines, a systematic search was conducted across PubMed, Springer, Google Scholar, and Semantic Scholar for studies published since 2015. Eligibility criteria targeted randomized controlled trials and prospective cohort studies assessing TRT in adult males after primary treatment for high-risk prostate cancer, with outcomes of cancer recurrence and/or QoL. After screening 763 records, 19 studies were included in the final analysis. Results: The synthesized evidence did not show a significant increase in biochemical recurrence with TRT. Several studies reported low recurrence rates, with one frequency-matched study finding that TRT was associated with a 1.4-year delay in recurrence. Conversely, a critical deficiency in QoL data was identified; 16 of the 19 included studies did not use validated assessment tools to measure patient-reported outcomes. Reported adverse events were generally low-grade and manageable. Conclusion: A notable discordance exists between the emerging oncological safety of TRT and the profound lack of evidence supporting its benefits for QoL in high-risk prostate cancer survivors. While the historical fear of cancer recurrence is not strongly supported by recent data, the therapy's actual benefit to patients remains largely unquantified. Future research must prioritize QoL as a primary endpoint to establish a definitive risk-benefit profile.References
Benjamin A. Teply, E. Antonarakis, M. Carducci, C. Paller, Hao Wang, H. Cao, A. Spitz, Jun Luo, M. Eisenberger, and S. Denmeade. “A Randomized Phase II Study Comparing Bipolar Androgen Therapy Vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial.” 2015.
J. Flores, C. Salter, N. Benfante, L. Jenkins, B. Ehdaie, V. Laudone, J. Eastham, and J. Mulhall. “PD49- 09 TESTOSTERONE THERAPY IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CAN-
CER.” Journal of Urology, 2022.
J. Flores, E. Vertosick, C. Salter, N. Liso, P. Teloken, B. Berookhim, Lawrence Jenkins, et al. “Testosterone Therapy in Men After Radical Prostatectomy for Low-Intermediate Organ-Confined Prostate Cancer.” Journal of Urology, 2024.
J. Mulhall, N. Benfante, P. Teloken, B. Berookhim, and L. Jenkins. “MP58-13 TESTOSTERONE THER- APY IN MEN WITH GLEASON 6-7 PROSTATE CANCER.” Journal of Urology, 2019.
JO Rust, T. Pereira, R. Smith, R. Boris, C. Egemba, J. Green, M. Koch, et al. “(062) THE RISK OF BIO- CHEMICAL RECURRENCE OF PROSTATE CANCER IN MEN RECEIVING TESTOSTERONE RE- PLACEMENT THERAPY FOLLOWING RADICAL PROSTATECTOMY.” Journal of Sexual Medicine, 2024.
Julia Chen, A. Joshua, S. Denmeade, E. Antonarakis, and M. Crumbaker. “High Dose Testosterone in Men with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Deficiency (HRD).” Journal of Clinical Oncology, 2019.
K. Pencina, A. Burnett, T. Storer, Wen Guo, Zhuoying Li, A. Kibel, Grace Huang, et al. “A Selective An- drogen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial.” Journal of Clinical Endocrinology and Metabolism, 2021.
Kristina Groti Antonič, Blaž Antonič, and M. Pfeifer. “Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial,” 2020.
L. Huynh, M. Towe, K. See, F. E. Khatib, and F. Yafi. “Is There a Role for Testosterone Replacement Therapy in Reducing Biochemical Recurrence Following Radical Prostatectomy?” Journal of Clinical Oncology, 2019.
L. O. Torres. “Do We Have Enough Evidences That Make You Safe to Treat a Man with Hypogonadism One Year After a Radical Prostatectomy for Prostate Cancer? | Opinion: YES.” International Brazilian Journal of Urology, 2018.
M. Alsinnawi, J. Cullen, L. Hurwitz, J. Banerji, K. Levie, E. Wolff, I. Rosner, et al. “Prospective Study of Health-Related Quality of Life in Men with High- and Intermediate-Risk Prostate Cancer Who Received Secondary Therapy.” 2016.
M. Crumbaker, Samantha Shekar, Mitchell G Lawrence, Leonard D Goldstein, Andrew O. Yam, Teesha D Downton, S. Begbie, et al. “A Phase II Single Arm Prospective Study of High Dose Testosterone in Combination with Carboplatin Chemotherapy in Late Line Metastatic Castrate-Resistant Prostate Cancer (HIGH-TeCH Study).” Journal of Clinical Oncology, 2025.
M. Hammad, J. Tran, M. Nguyen, R. Gevorkyan, C. Fung, F. Yafi, L.M. Huynh, and T. Ahlering. “(085) Long-Term Outcomes of Testosterone Replacement Therapy Delaying Biochemical Recurrence Post- RARP: Frequency-Matched Case-Control Study.” Journal of Sexual Medicine, 2024.
M. Markowski, M. Taplin, Rahul R Aggarwal, L. Sena, Hao Wang, Hanfei Qi, A. Lalji, et al. “Bipolar Androgen Therapy Plus Nivolumab for Patients with Metastatic Castration-Resistant Prostate Cancer: The COMBAT Phase II Trial.” Nature Communications, 2024.
M. Schweizer, Hao Wang, Brandon S. Luber, R. Nadal, A. Spitz, D. Rosen, H. Cao, et al. “Bipolar Androgen Therapy (BAT) in Men with Hormone Sensitive (HS) Prostate Cancer (PC).” 2016.
Mostafa Aglan, Yixin Kong, and Brendan Connell. “Testosterone Therapy in Patients with Locoregional Prostate Cancer Treated with Prior Androgen Deprivation Therapy and Radiation: A Retrospective Single Center Review.” Translational Andrology and Urology, 2025.
N. Candelario, Andrew Nicklawsky, L. Graham, E. Lam, E. Callihan, M. Wacker, T. Flaig, and E. Kessler. “Transdermal Square-Wave Testosterone Therapy: A Pilot Trial in Metastatic Castration-Resistant Prostate Cancer.” Journal of Clinical Oncology, 2023.
R. Aggarwal, S. Eggener, Ronald C. Chen, G. Heller, Akash Patnaik, Han Xiao, D. Weckstein, et al. “A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer: An Alliance Foundation Trial (AFT-19).” 2018.
Zganjar, A., Touss, A., Ziegelmann, M., Yang, D., Manka, M., Kohler, T., Helo, S. and Trost, L. (2019) 'Efficacy of Restorex penile traction therapy in improving penile length and erectile function post prostatectomy', The Journal of Urology, 201(Supplement 4), p. e722.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Salman Alfarisi Kuddah, John M. Sangkai (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
